{"id":"syr-322-met","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL216253","moleculeType":"Small molecule","molecularWeight":"338.41"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by mimicking the action of the natural hormone GLP-1 to help lower blood sugar levels. This is achieved by enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon secretion, and slowing gastric emptying.","oneSentence":"SYR-322-MET is a glucagon-like peptide-1 (GLP-1) receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:07.964Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07289750","phase":"PHASE4","title":"The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-05-01","conditions":"T2DM, MAFLD","enrollment":80},{"nctId":"NCT02276274","phase":"PHASE3","title":"Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-06","conditions":"Clinical Pharmacology","enrollment":12},{"nctId":"NCT05363592","phase":"PHASE1","title":"A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"Celltrion","startDate":"2022-06-25","conditions":"Healthy","enrollment":48},{"nctId":"NCT05363384","phase":"PHASE1","title":"A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"Celltrion","startDate":"2022-06-11","conditions":"Healthy","enrollment":48},{"nctId":"NCT02823808","phase":"PHASE4","title":"Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function","status":"UNKNOWN","sponsor":"Kyunghee University Medical Center","startDate":"2017-07","conditions":"Diabetes","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SYR-322-MET","genericName":"SYR-322-MET","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SYR-322-MET is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}